EDGAR·FLOW

Phio Pharmaceuticals Corp. — Form 8-K

Filed September 28, 2026 · analyzed by the 8-K Agent
8-K — Neutral significance 72/100
What the filing says
Phio Pharmaceuticals' Board and Compensation Committee approved an amendment to increase the 2020 Long-Term Incentive Plan share reserve by 1,500,000 shares, raising the total available from 952,017 to 2,452,017 shares, pending shareholder approval. This allows for up to $500,000 annual equity grants to non-employee directors and increases equity pool available for employee and director compensation. The amendment is effective only upon stockholder approval.
Why this rating

1.5M share increase is ~13% of current market value ($11.2M); material for compensation but routine governance. Neutral because outcome depends on shareholder vote; no imminent business impact.

Price action (we called it neutral)
before filing · preread
$1.01 ▲ 0.00%
at our read · unknown
$1.01
+10 min · unknown
$1.04 ▲ 2.97%
+30 min · unknown
$1.03 ▲ 2.48%
+1 hr · unknown
$1.04 ▲ 2.97%
+4 hrs · unknown
$1.02 ▲ 0.99%

The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ PHIO · stock on Yahoo Finance ↗

See more from September 28, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.